Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs)
Autor: | Ki-Hun Kim, Sun Jin Sym, Byung Sik Kim, Tae Won Kim, Hee Cheol Kim, Heung Moon Chang, Yoon-Koo Kang, Min-Hee Ryu, Jae-Lyun Lee, Jeong Hwan Yook |
---|---|
Rok vydání: | 2008 |
Předmět: |
Adult
Male medicine.medical_specialty Lung Neoplasms Neoplasm Residual Receptor Platelet-Derived Growth Factor alpha Gastrointestinal Stromal Tumors Premedication Antineoplastic Agents Digestive System Neoplasms Disease-Free Survival Drug Administration Schedule Piperazines medicine Humans Gastrointestinal stromal tumors (GISTs) Survival rate Aged GiST business.industry Imatinib General Medicine Middle Aged Prognosis Debulking medicine.disease Surgery Survival Rate Proto-Oncogene Proteins c-kit Pyrimidines Imatinib mesylate Oncology Drug Resistance Neoplasm Benzamides Mutation Imatinib Mesylate Female Neoplasm Recurrence Local business Progressive disease Follow-Up Studies medicine.drug |
Zdroj: | Journal of Surgical Oncology. 98:27-33 |
ISSN: | 1096-9098 0022-4790 |
Popis: | Background We investigated the role of surgical intervention for advanced GIST after imatinib. Methods Among 256 patients treated with imatinib for advanced GIST, the medical records of the 34 patients who underwent surgery of residual tumors after imatinib treatment were reviewed. Results Surgery was performed on 24 patients with responsive disease (RD) after imatinib, on 3 with focal progressive disease (FP), and on 7 with generalized progressive disease (GP). All gross tumors were completely resected in 19/24 (79%), 1/3 (33%), and 1/7 (14%) patients, respectively. Disease status at surgery was associated with prognosis after surgery; with a median follow-up of 25.7 months, the median progression-free survival of patients resected for RD, FP, and GP were 27.8 months (95% CI, 17.8–37.8 months), 5.1 months (95% CI, 4.7–5.6 months), and 3.3 months (95% CI, 2.7–3.9 months), respectively (P |
Databáze: | OpenAIRE |
Externí odkaz: |